Table 1 Clinical characteristics of the 36 patients diagnosed with NK/T cell lymphoma 'nasal type'
Number of patients | 36 |
Median age (years ; range) | 49 (22–80) |
Age > 60 years, n (%) | 9 (25) |
Gender (male – female) | 24 – 11 |
WHO performance status, n (%) | |
0- 1 | 27 (75) |
2 | 6 (17) |
3–4 | 3 (8) |
Local invasiveness in Upper NK / T lymphoma: T3 and T4, n (%) | 21 (72) |
Signs and symptoms, n (%) | |
Purulent rhinorrhea | 20 (55) |
Nasal obstruction or edema | 25 (69) |
Sinusitis | 12 (33) |
Epistaxis | 11 (30) |
Pharyngitis | 5 (14) |
Orbital edema or uveitis | 5 (14) |
Dysphagia | 2 (5) |
Nerve VII, palsy | 2 (5) |
B symptoms, n (%) | 14 (39) |
Anatomic category, n (%) | |
Upper NK/T lymphoma | 29 (80) |
Extra upper NK/T lymphoma | 7 (20) |
Sites of localization, n (%) | |
Nose | 25 (69) |
Paranasal sinus | 21 (58) |
Nodes | 16 (44) |
Palate – pharyngeal | 9 (25) |
Bone marrow | 8 (22) |
Orbit | 4 (11) |
Skin | 4 (11) |
Lung | 4 (11) |
Central nervous involvement | 4 (11) |
Liver | 4 (11) |
Gastrointestinal tract | 3 (8) |
Spleen | 2 (5) |
Testis | 1 (3) |
Suprarenal gland | 1(3) |
Regional lymphadenopathy, n (%) | 16 (44) |
Biology, n (%) | |
LDH > Upper limit of normal | 14 (39) |
Lymphopenia | 22 (61) |
B2 microglobuline > upper limit of normal | 21 (58) |
CRP > upper limit of normal | 18 (50) |
Anemia | 13 (36) |
Serum albumin <30 mg/L | 12 (33) |
Hemophagocytic syndrome, n (%) | 3 (8) |
Ann Arbor staging, n (%) | |
IE | 10 (28) |
IIE | 6 (17) |
IV | 20 (55) |
IPI score, n (%) | |
0 – 1 (low risk) | 16 (44) |
2 (low intermediate risk) | 7 (20) |
3 (high intermediate risk) | 7 (20) |
4 -5 (high risk) | 6 (16) |
Korean NK/T cell prognostic index, n (%) | |
0 (low risk) | 5 (14) |
1 (low intermediate risk) | 14 (39) |
2 (high intermediate risk) | 8 (22) |
3 – 4 (high risk) | 9 (25) |
PIT score, n (%) | |
0 (low risk) | 13 (37) |
1 (low intermediate) | 11 (31) |
2 (high intermediate risk) | 8 (22) |
3 – 4 (high risk) | 3 (8) |